PubRank

Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.

PubWeight™: 0.79‹?›

🔗 View Article (PMID 28162975)

Published in Cancer Cell on February 02, 2017

Authors

Lauren Fishbein1, Ignaty Leshchiner2, Vonn Walter3, Ludmila Danilova4, A Gordon Robertson5, Amy R Johnson6, Tara M Lichtenberg7, Bradley A Murray2, Hans K Ghayee8, Tobias Else9, Shiyun Ling10, Stuart R Jefferys3, Aguirre A de Cubas11, Brandon Wenz12, Esther Korpershoek13, Antonio L Amelio3, Liza Makowski14, W Kimryn Rathmell11, Anne-Paule Gimenez-Roqueplo15, Thomas J Giordano16, Sylvia L Asa17, Arthur S Tischler18, Cancer Genome Atlas Research Network, Karel Pacak19, Katherine L Nathanson20, Matthew D Wilkerson21

Author Affiliations

1: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
2: The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.
3: Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
4: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21287, USA.
5: Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada.
6: Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
7: The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.
8: Division of Endocrinology & Metabolism, Department of Medicine, University of Florida College of Medicine & Malcom Randall VA Medical Center, Gainesville, FL 32608, USA.
9: Division of Metabolism, Endocrinology, & Diabetes, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109, USA.
10: University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
11: Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Division of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
12: Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
13: Department of Pathology, Erasmus MC University Medical Center Rotterdam, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands.
14: Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
15: INSERM, UMR970, Paris-Cardiovascular Research Center, F-75015 Paris, France.
16: Department of Pathology, University of Michigan Health System, Ann Arbor, MI 48109, USA.
17: Department of Pathology, University Health Network, Toronto, ON M5G 2C4, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5G 2C4, Canada.
18: Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA 02111, USA.
19: Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD 20892, USA. Electronic address: karel@mail.nih.gov.
20: Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: knathans@exchange.upenn.edu.
21: Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: mdwilkerson@outlook.com.

Articles citing this ↘

UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (2017) 0.76

MYC Deregulation in Primary Human Cancers. Genes (Basel) (2017) 0.75

SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. J Cancer Res Clin Oncol (2017) 0.75

Articles cited by this ↗

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98

Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16

Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87

MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res (2010) 9.80

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88

Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell (2009) 3.68

SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell (2013) 3.24

Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol (2005) 3.20

ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics (2010) 3.17

A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85

Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science (2015) 2.24

Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem (2011) 2.24

Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab (2010) 2.09

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther (2014) 2.03

Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc (1983) 2.01

Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res (2012) 1.80

Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J Clin Endocrinol Metab (2013) 1.69

Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer (2011) 1.49

Mastermind-like transcriptional co-activators: emerging roles in regulating cross talk among multiple signaling pathways. Oncogene (2008) 1.48

Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet (2011) 1.38

Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer (2014) 1.29

Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol (2014) 1.27

Mastermind-like 1 Is a specific coactivator of beta-catenin transcription activation and is essential for colon carcinoma cell survival. Cancer Res (2007) 1.26

Altered Notch signaling resulting from expression of a WAMTP1-MAML2 gene fusion in mucoepidermoid carcinomas and benign Warthin's tumors. Exp Cell Res (2004) 1.15

Eukaryotic cold shock domain proteins: highly versatile regulators of gene expression. Bioessays (2010) 1.10

Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell (2016) 1.06

Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun (2015) 1.06

Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Res (2014) 1.05

Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet (2013) 1.05

ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics (2014) 1.04

Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet (2012) 1.03

Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci (2014) 1.00

Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma. Nat Genet (2014) 0.99

Detection of RET proto-oncogene point mutations in paraffin-embedded pheochromocytoma specimens by nonradioactive single-strand conformation polymorphism analysis and direct sequencing. Am J Pathol (1994) 0.97

Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun (2015) 0.87

Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma. Endocr Relat Cancer (2014) 0.87

One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2013) 0.84

The genomic landscape of phaeochromocytoma. J Pathol (2015) 0.83

Unr, a cytoplasmic RNA-binding protein with cold-shock domains, is involved in control of apoptosis in ES and HuH7 cells. Oncogene (2006) 0.83

Succinate: a new epigenetic hacker. Cancer Cell (2013) 0.83

miR-375 regulates the canonical Wnt pathway through FZD8 silencing in arthritis synovial fibroblasts. Immunol Lett (2015) 0.82

The RNA-binding protein Unr prevents mouse embryonic stem cells differentiation toward the primitive endoderm lineage. Stem Cells (2011) 0.82

CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvement. Proc Natl Acad Sci U S A (2014) 0.81

Analysis of selected genes in neuroendocrine tumours: insulinomas and phaeochromocytomas. J Neuroendocrinol (2008) 0.81

Genetic aberrance of sporadic MEN 2A component tumours: analysis of RET. Pathology (2005) 0.81

Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma. Physiol Res (2008) 0.80

Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res (2015) 0.80

PRKACA: the catalytic subunit of protein kinase A and adrenocortical tumors. Front Cell Dev Biol (2015) 0.78

Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma. Mol Cancer Res (2016) 0.78

The control of precerebellar neuron migration by RNA-binding protein Csde1. Neuroscience (2013) 0.76

Articles by these authors ⇆

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40

Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12

Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29

Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60

Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93

Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02

Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71

Landscape of somatic retrotransposition in human cancers. Science (2012) 4.37

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell (2014) 4.17

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85

Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64

The Molecular Taxonomy of Primary Prostate Cancer. Cell (2015) 3.29

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00

Integrated genomic characterization of oesophageal carcinoma. Nature (2017) 2.76

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell (2016) 2.27

The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell (2014) 2.21

Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One (2012) 1.76

Spectrum of somatic mitochondrial mutations in five cancers. Proc Natl Acad Sci U S A (2012) 1.63

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet (2016) 1.16

Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell (2016) 1.06

Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Res (2014) 1.05

Integrated genomic and molecular characterization of cervical cancer. Nature (2017) 0.96

Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell (2017) 0.92

Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell (2017) 0.81

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep (2017) 0.76

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell (2017) 0.76

EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression. Hum Mol Genet (2016) 0.76

SigFuge: single gene clustering of RNA-seq reveals differential isoform usage among cancer samples. Nucleic Acids Res (2014) 0.76

Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell (2016) 0.76

Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell (2017) 0.75